Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
暂无分享,去创建一个
Rob Pieters | Todd R Golub | John H Kersey | Andrew L Kung | Scott A Armstrong | T. Golub | S. Armstrong | S. Korsmeyer | J. Fletcher | R. Stam | S. Sallan | M. D. Den Boer | R. Pieters | L. Silverman | J. Griffin | A. Kung | J. Kersey | M. Mabon | Stanley J Korsmeyer | James D Griffin | Stephen E Sallan | Lewis B Silverman | Jonathan A Fletcher | Ronald W Stam | Meghann E Mabon | Monique L Den Boer | M. D. den Boer
[1] C. Pui,et al. Biology and Clinical Significance of Cytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia , 1990 .
[2] H. Beug,et al. MLL–ENL cooperates with SCF to transform primary avian multipotent cells , 2002, The EMBO journal.
[3] B. Smith,et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.
[4] M. Eguchi,et al. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia , 2000, Leukemia.
[5] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[6] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[7] D. Birnbaum,et al. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. , 1994, Leukemia.
[8] T Friedmann,et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[9] D. Birnbaum,et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. , 1995, Leukemia.
[10] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[11] A. Harris,et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Naoe,et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain , 2002, Oncogene.
[13] S. Goff,et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.
[14] S. McCullough,et al. Sensitivity of FISH in detection of MLL translocations , 2000, Genes, chromosomes & cancer.
[15] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[16] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[17] C. Pui,et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.
[18] Intensified therapy for infants with acute lymphoblastic leukemia , 1997, Cancer.
[19] S. Raimondi,et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.
[20] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[21] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[22] D. Birnbaum,et al. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.
[23] D. Pardoll,et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations , 1991, Cell.
[24] G. Mcmahon,et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. , 2002, Blood.
[25] Doriano Fabbro,et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.
[26] J J Shuster,et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. , 1991, Blood.
[27] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[28] F. Cotter,et al. BCL‐2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;ll)(q21;q23) translocation , 1995, British journal of haematology.
[29] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[30] T. Hawley,et al. Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.
[31] D. Arthur,et al. Establishment of a leukemic cell model for studying human pre-B to B cell differentiation. , 1989, Journal of immunology.
[32] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[33] C. Bartram,et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin‐7 , 1994, British journal of haematology.
[34] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Ratajczak,et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] Donna Neuberg,et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.
[37] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[38] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[39] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[40] J. Rowley,et al. The critical role of chromosome translocations in human leukemias. , 1998, Annual review of genetics.
[41] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[42] S. Korsmeyer,et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. , 1993, Blood.
[43] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[44] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[45] T. Golub,et al. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. , 2002, Cancer cell.
[46] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[47] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[48] M. K. Hibbard,et al. PLAG1 fusion oncogenes in lipoblastoma. , 2000, Cancer research.